Formulary Committee members with a potential conflict of interest permission to participate in committee communications and discussions
Introduction and first reading; Referred to
Email me when SF 4978 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track SF 4978. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill changes Minnesota law so that members of the Formulary Committee who have a potential conflict of interest can still take part in committee communications and discussions, provided they disclose the conflict. It also creates a public comment process for committee recommendations and requires input from the Minnesota Rare Disease Advisory Council on certain drug decisions. The changes aim to increase transparency while preserving expertise on the committee.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about SF 4978
3 free questions a day, no accountHistory
- Referred to Health and Human Services
- Introduction and first reading
Sponsors
- Boldon · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when SF 4978 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track SF 4978 freeOr ask your AI assistant about SF 4978 directly:
Add to Claude, ChatGPT or Cursor